131 related articles for article (PubMed ID: 17285459)
1. New Agents in Clinical Oncology. 24 November 2006, London, UK.
Martin S
IDrugs; 2007 Feb; 10(2):99-101. PubMed ID: 17285459
[No Abstract] [Full Text] [Related]
2. [131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
McCluskey AG; Boyd M; Gaze MN; Mairs RJ
Cancer Lett; 2005 Oct; 228(1-2):221-7. PubMed ID: 15935554
[TBL] [Abstract][Full Text] [Related]
3. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
McCluskey AG; Boyd M; Ross SC; Cosimo E; Clark AM; Angerson WJ; Gaze MN; Mairs RJ
Clin Cancer Res; 2005 Nov; 11(21):7929-37. PubMed ID: 16278418
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenesis drugs target specific cancers, mechanisms.
Randal J
J Natl Cancer Inst; 2000 Apr; 92(7):520-2. PubMed ID: 10749899
[No Abstract] [Full Text] [Related]
5. Anti-angiogenesis: the challenges ahead.
Mariani SM
MedGenMed; 2003 Apr; 5(2):22. PubMed ID: 14603121
[No Abstract] [Full Text] [Related]
6. Inhibition of poly(ADP-ribose) polymerase in cancer.
Plummer ER
Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
[TBL] [Abstract][Full Text] [Related]
7. Disrupting tumour blood vessels.
Tozer GM; Kanthou C; Baguley BC
Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
[TBL] [Abstract][Full Text] [Related]
8. 25 years of oncology.
Spittle MF
Br J Hosp Med; 1991 Oct; 46(4):249, 251. PubMed ID: 1954491
[No Abstract] [Full Text] [Related]
9. Genetic enhancement of radionuclide cancer therapy.
Wheldon TE; Mairs RJ; Boyd M
Lancet; 1999 Dec; 354(9194):1999-2000. PubMed ID: 10622325
[No Abstract] [Full Text] [Related]
10. DNA topoisomerase I-targeting drugs as radiation sensitizers.
Chen AY; Choy H; Rothenberg ML
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
[TBL] [Abstract][Full Text] [Related]
11. Poly adenosine diphosphate-ribose polymerase inhibitors and heat shock protein 90 inhibitors.
Riely GJ
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1803-4. PubMed ID: 22005537
[No Abstract] [Full Text] [Related]
12. Cancer: one step at a time.
Mooney D
Nature; 2005 Jul; 436(7050):468-9. PubMed ID: 16049458
[No Abstract] [Full Text] [Related]
13. American Association of Cancer Research--95th annual meeting. Highlights. 27-31 March, 2004, Orlando, FL, USA.
Kibble A; Davies J
IDrugs; 2004 May; 7(5):416-9. PubMed ID: 15154096
[No Abstract] [Full Text] [Related]
14. Differential response of tumor cells and normal fibroblasts to fractionated combined treatment with topotecan and ionizing radiation.
Ohneseit PA; Wildemann A; Herskind C; Bamberg M; Rodemann HP
Int J Radiat Biol; 2002 Feb; 78(2):125-32. PubMed ID: 11779362
[TBL] [Abstract][Full Text] [Related]
15. Medical oncology in the 1990s.
Braverman AS
Lancet; 1991 Apr; 337(8746):901-2. PubMed ID: 1672980
[No Abstract] [Full Text] [Related]
16. [Topotecan: a new discovery and future prospects].
Bianco AR
Tumori; 1999; 85(6 Suppl 1):S1-2. PubMed ID: 10786193
[No Abstract] [Full Text] [Related]
17. [Present and future of therapeutic oncology].
García G; Beltrán-Ortega A; Díaz-Perches R; de la Garza-Salazar JG; Noriega-Limón J; Jiménez-Zamudio L
Gac Med Mex; 1984; 120(7-8):281-300. PubMed ID: 6526215
[No Abstract] [Full Text] [Related]
18. Radiation combined with antiangiogenic and antivascular agents.
O'Reilly MS
Semin Radiat Oncol; 2006 Jan; 16(1):45-50. PubMed ID: 16378906
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II inhibitors.
Martincic D; Hande KR
Cancer Chemother Biol Response Modif; 2005; 22():101-21. PubMed ID: 16110609
[No Abstract] [Full Text] [Related]
20. DNA topoisomerase I inhibitors.
Takimoto CH; Kieffer LV; Arbuck SG
Cancer Chemother Biol Response Modif; 1997; 17():80-113. PubMed ID: 9551210
[No Abstract] [Full Text] [Related]
[Next] [New Search]
